Stocks Health care MYGN
NASDAQ · Health careMyriad Genetics Inc (MYGN)
Myriad Genetics Inc brought in $803.6M of revenue over the twelve months to September 30, 2026, down 2.6% from a year earlier. It posted a net loss of $129.1M. At September 30, 2026 it held $107.1M in cash against $121.1M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 6, 2026.
Key facts about Myriad Genetics Inc
- Net worth
- Myriad Genetics Inc has a market value (market cap) of $542.3M at the latest share price, and shareholders' equity of $269M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $824.5M (-1.6% year on year), with a net loss of $365.9M. Over the 12 months to September 30, 2026: revenue $803.6M, net loss $129.1M.
- Cash flow
- In fiscal 2025 operations brought in $1.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 6, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Myriad Genetics Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Myriad Genetics Inc does
Myriad Genetics Inc is registered with the SEC under industry code SIC 2835 (In Vitro & In Vivo Diagnostic Substances). Its shares trade on NASDAQ under the ticker MYGN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $824.5M | -$365.9M | -$3.95 | n/a |
| 2024 | $837.6M | -$127.3M | -$1.41 | n/a |
| 2023 | $753.2M | -$263.3M | -$3.18 | n/a |
| 2022 | $678.4M | -$112M | -$1.39 | -$151.6M |
| 2021 | $690.6M | -$27.2M | -$0.35 | $600K |
| 2020 | $557.1M | -$223.6M | -$2.99 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where MYGN ranks in Health care
Latest SEC filings
What Myriad Genetics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 6, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 1.5% to $202.7M versus the same quarter last year; diluted EPS -$0.46 versus -$0.29.
- November 5, 2026Other event 8-K
- November 4, 2026
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- October 20, 2026
- October 9, 2026Executive or director change8-KMyriad Genetics entered into a separation agreement with former Chief Commercial Officer Brian Donnelly that includes a severance payment of $1,322,294.
- September 16, 2026
- September 4, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Myriad Genetics Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 5 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 1, 2026 | Fox Jennifer LynneChief Legal & Corp Strategy | Received as pay | 39,370 | - |
| September 21, 2026 | Wheeler Benjamin RichardChief Financial Officer | Shares withheld for tax | 2,555 | $10.2K |
| September 16, 2026 | Sikri VishalEVP, Commercial | Received as pay | 257,731 | - |
| September 3, 2026 | Fox Jennifer LynneChief Legal Officer | Shares withheld for tax | 4,398 | $14.2K |
| August 16, 2026 | Wheeler Benjamin RichardChief Financial Officer | Shares withheld for tax | 8,761 | $26.5K |
| June 11, 2026 | Raha Samraat S.President and CEO, Director | Received as pay | 3,542 | $13.9K |
| June 11, 2026 | Donnelly Brian JChief Commerical Officer | Received as pay | 5,000 | $19.7K |
| June 8, 2026 | Kumar RashmiDirector | Soldpre-planned (10b5-1) | 15,000 | $66.8K |
Who owns MYGN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| BlackRock Portfolio Management LLC13G, passive | 10.4% | September 4, 2026 |
| Millennium Management LLC13G, passive with 3 related filers | 7.2% | February 11, 2026 |
| Vestal Point Capital, LP13G, passive with 1 related filers | 6.1% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 197 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 10,890,440 | +2,000,796 |
| Millennium Management LLC | 6,620,372 | -48,445 |
| Vestal Point Capital, LP | 5,735,000 | +4,087,000 |
| State Street Corp | 4,985,060 | +561,033 |
| D. E. Shaw & Co., Inc. | 4,582,083 | +82,359 |
| Vanguard Capital Management LLC | 4,081,376 | +156,851 |
| Vanguard Portfolio Management LLC | 3,079,670 | +497,439 |
| Aqr Capital Management LLC | 2,766,689 | +854,393 |
| Morgan Stanley | 2,481,104 | -687,638 |
| Geode Capital Management, LLC | 2,416,197 | +96,818 |
| Assenagon Asset Management S.A. | 2,062,928 | +615,967 |
| Goldman Sachs Group Inc | 2,056,843 | -309,249 |
| Jacobs Levy Equity Management, Inc | 1,891,527 | -196,965 |
| Charles Schwab Investment Management Inc | 1,740,794 | -60,684 |
| Qube Research & Technologies Ltd | 1,665,835 | -24,626 |
| Federated Hermes, Inc. | 1,570,314 | -405,852 |
| Two Sigma Investments, LP | 1,557,727 | +273,677 |
| Nuveen, LLC | 1,545,549 | +626,586 |
| Mackenzie Financial Corp | 1,535,702 | new |
| Citadel Advisors LLC | 1,533,684 | +1,080,642 |
Insiders
18 insiders reported holding 5,828,737 shares in total, about $33M at the last price.
| Holder | Shares |
|---|---|
| Raha Samraat S.President and CEO, Director | 1,068,083 |
| Verratti MarkChief Operating Officer | 629,646 |
| Donnelly Brian JChief Commerical Officer | 573,363 |
| Sikri VishalEVP, Commercial | 351,224 |
| Fox Jennifer LynneChief Legal & Corp Strategy | 345,334 |
| Phanstiel S. LouiseDirector | 341,652 |
| Muzzey DaleChief Scientific Officer | 326,310 |
| Wheeler Benjamin RichardChief Financial Officer | 287,193 |
| Solaiman ShereenChief People Officer | 267,801 |
| Jampa RajChief Technology Officer | 251,889 |
Questions about MYGN
What does Myriad Genetics Inc do?
Myriad Genetics Inc is a company in the Health care sector, listed on NASDAQ as MYGN. Its shares trade on NASDAQ under the ticker MYGN.
What is Myriad Genetics Inc's net worth?
Myriad Genetics Inc has a market value (market cap) of $542.3M at the latest share price, and shareholders' equity of $269M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Myriad Genetics Inc profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $129.1M on revenue of $803.6M.
How much revenue does Myriad Genetics Inc make?
Over the twelve months to September 30, 2026 Myriad Genetics Inc reported revenue of $803.6M. That is 2.6% less than a year earlier.
When did Myriad Genetics Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 6, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the executive or director change from November 9, 2026.
When is Myriad Genetics Inc's next earnings report?
Myriad Genetics Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare MYGN with
Follow MYGN
Get an email when Myriad Genetics Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Myriad Genetics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.